MRI measurements of inflammatory precursors to rheumatoid arthritis are central to the early application of a promising anti-arthritis therapy, according to a study published in the British Medical Journal.
MRI measurements of inflammatory precursors to rheumatoid arthritis are central to the early application of a promising anti-arthritis therapy, according to a study published in theBritish Medical Journal.
A British-led international team studying the effectiveness of the immunosuppressant golimumab (trade name Simponi) found magnetic resonance imaging to be better than traditional X-rays in capturing the drug’s effect on inflammatory lesions (osteitis and synovitis) as well as erosions associated with rheumatoid arthritis.
While X-ray studies remain the standard for assessing destructive skeletal changes in patients with rheumatoid arthritis, they are “inherently limited by the lack of ability to assess pre-erosive changes that precede damage to the osseous component of the joint, a stage of disease that had been thought to be irreversible,” Philip G Conaghan, MD, PhD, of the University of Leeds, and colleagues wrote.
The team reviewed results in the GO-FORWARD study of golimumab in the treatment of patients with established rheumatoid arthritis, which included an MRI substudy. In the study, 444 patients were randomly assigned to groups taking combinations of golimumab, methotrexate (MTX), and placebo; 240 of the patients were also enrolled in the MRI substudy.
Golimumab plus MTX significantly improved MRI-detected synovitis and osteitis (prognosticators of future structural damage) versus placebo plus MTX at weeks 12 and 24, the researchers found. They added that “MRI allows measurement of inflammatory lesions such as osteitis and synovitis, as well as erosions, and thus is an important tool for objectively evaluating the effect of newer compounds on disease activity in future clinical trials enrolling patient populations with relatively lower disease activity.”
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.